FDA Names PreCheck Participants - Report - MDSpire

FDA Names PreCheck Participants

Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.

  • By

  • Kathryn Wighton

  • June 30, 2026

  • 3 min

Share

Clinical Report: FDA Names PreCheck Participants

Overview

The FDA has selected seven companies for its PreCheck Pilot Program aimed at enhancing U.S. pharmaceutical manufacturing.

Background

The FDA PreCheck Pilot Program addresses the need for improved domestic pharmaceutical manufacturing capabilities. By engaging with companies early in the facility development process, the FDA aims to mitigate risks associated with drug shortages and enhance access to essential therapies.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Seven companies were selected for the FDA PreCheck Pilot Program.
  • The program aims to support the development of new U.S. pharmaceutical manufacturing facilities.
  • Participants will receive early technical guidance and have opportunities for expedited facility evaluations.
  • The initiative is intended to reduce uncertainty related to manufacturing readiness.
  • Eligible companies must commit to submitting relevant drug applications tied to their new facilities.

Clinical Implications

The PreCheck Pilot Program may streamline the regulatory process for new drug manufacturing facilities.

Conclusion

The FDA's PreCheck Pilot Program aims to enhance the U.S. drug supply chain by fostering early collaboration with pharmaceutical manufacturers.

Related Resources & Content

  1. US Food and Drug Administration, FDA, 2026 -- FDA Names PreCheck Participants
  2. npj Digital Medicine — Fibricheck detection capabilities for atrial fibrillation (FDA–AF): a multicenter validation study
  3. Associated Press Health — FDA plans bonuses to staffers who complete speedy drug reviews
  4. The ASCO Post — FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers
  5. Retinal Physician — Clinical Trial Update April 2023
  6. FDA PreCheck Pilot Program Structure | FDA
  7. FDA PreCheck Pilot Program | FDA
  8. CDER Quality Management Maturity | FDA

Original Source(s)

FDA Names PreCheck Participants

  • by Kathryn Wighton

  • June 30, 2026

Related Content

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"